Circassia's Allergy Therapy Begins Phase II Clinical Trial In Asthma Patients
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment